Ferric carboxymaltose is under clinical development by Vifor Pharma Management and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ferric carboxymaltose’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Anemia took place on 05 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ferric carboxymaltose Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ferric carboxymaltose overview

Ferric carboxymaltose (Ferinject, Injectafer, Renegy, Feryxa) is an iron replacement product. It is formulated as solution for intravenous route of administration. Ferric carboxymaltose is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. It is under development for the treatment of restless legs syndrome, iron deficiency anemia, chemotherapy induced anemia, heart failure with iron deficiency and reduced ejection fraction.

Vifor Pharma Management overview

Vifor Pharma Management (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines for unmet medical needs of the gastrointestinal tract. It operates production plants in Portugal and Switzerland, and carries out business through subsidiaries. Vifor Pharma is headquartered in St. Gallen, Switzerland.

Quick View Ferric carboxymaltose LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Ferric carboxymaltose
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Hematological Disorders
  • Toxicology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.